Value of dynamic contrast-enhanced MRI and DWI in diagnosis of prostate cancer and its pathological comparison

This study aims to assess the diagnostic utility of dynamic contrast-enhanced magnetic resonance imaging (DCE-MRI) and diffusion-weighted imaging (DWI) in the detection of prostate cancer (PCa) and to investigate the correlation between DCE-MRI signal intensity-time (SI-T) curve parameters and angiogenesis in cancerous lesions. A total of 56 PCa patients and 50 benign prostatic hyperplasia (BPH) patients were enrolled, and their DCE-MRI and DWI images before surgery were analyzed. We also examined the association between DCE-MRI SI-T curve parameters and vascular endothelial growth factor (VEGF) or microvessel density (MVD). In the early stage of DCE-MRI, both PCa and BPH lesions exhibited higher enhancement levels compared to the surrounding normal prostate tissue, and during delayed scanning, BPH lesions and adjacent normal prostate tissue demonstrated substantial enhancement with minimal distinction. Conversely, PCa lesions exhibited relatively low signal intensity changes, distinguishing them from the surrounding normal tissue. Most SI-T curve patterns for PCa patients exhibited ascending and descending profiles, whereas BPH patients predominantly exhibited plateau or ascending curves (p < 0.05). PCa patients had lower peak times, higher enhancement degrees and rates, and elevated VEGF positivity rates and MVD counts compared to BPH patients (p < 0.05). Correlation analysis revealed a negative correlation between peak times of SI-T curve parameters and VEGF and MVD expression levels, while enhancement degree and rate exhibited positive correlations with these parameters (p < 0.05). In DWI images, hyperplastic foci were primarily isointense or slightly hyperintense, while cancerous foci were predominantly markedly hyperintense. Higher b-values were associated with lower apparent diffusion coefficient (ADC) values. However, across various b-values, PCa consistently exhibited lower ADC values than BPH (p < 0.05). DCE-MRI and DWI are valuable tools for distinguishing between PCa and BPH.

MRI; Dynamic enhancement; DWI; Prostatic carcinoma; Angiogenesis within cancer foci

[1] Monni F, Fontanella P, Grasso A, Wiklund P, Ou Y, Randazzo M, et al. Magnetic resonance imaging in prostate cancer detection and management: a systematic review. Minerva Urology and Nephrology. 2017; 69: 567–578.

[2] Panebianco V, Villeirs G, Weinreb JC, Turkbey BI, Margolis DJ, Richenberg J, et al. Prostate magnetic resonance imaging for local recurrence reporting (PI-RR): international consensus-based guidelines on multiparametric magnetic resonance imaging for prostate cancer recurrence after radiation therapy and radical prostatectomy. European Urology Oncology. 2021; 4: 868–876.

[3] O’Connor L, Wang A, Walker SM, Yerram N, Pinto PA, Turkbey B. Use of multiparametric magnetic resonance imaging (mpMRI) in localized prostate cancer. Expert Review of Medical Devices. 2020; 17: 435–442.

[4] Yoshida S, Takahara T, Arita Y, Sakaino S, Katahira K, Fujii Y. Whole-body diffusion-weighted magnetic resonance imaging: diagnosis and follow up of prostate cancer and beyond. International Journal of Urology. 2021; 28: 502–513.

[5] Stempel CV, Dickinson L, Pendsé D. MRI in the management of prostate cancer. Seminars in Ultrasound, CT and MRI. 2020; 41: 366–372.

[6] Emmett L, Buteau J, Papa N, Moon D, Thompson J, Roberts MJ, et al. The additive diagnostic value of prostate-specific membrane antigen positron emission tomography computed tomography to multiparametric magnetic resonance imaging triage in the diagnosis of prostate cancer (PRIMARY): a prospective multicentre study. European Urology. 2021; 80: 682–689.

[7] Bangma CH, van Leenders GJLH, Roobol MJ, Schoots IG. Restricting false-positive magnetic resonance imaging scans to reduce overdiagnosis of prostate cancer. European Urology. 2021; 79: 30–32.

[8] Fernandes CD, Mischi M, Wijkstra H, Barentsz JO, Heijmink SWTPJ, Turco S. Radiomic combination of spatial and temporal features extracted from DCE-MRI for prostate cancer detection. Annual International Conference of the IEEE Engineering in Medicine & Biology Society. 2021; 2021: 3153–3156.

[9] Huebner NA, Korn S, Resch I, Grubmüller B, Gross T, Gale R, et al. Visibility of significant prostate cancer on multiparametric magnetic resonance imaging (MRI)—do we still need contrast media? European Radiology. 2021; 31: 3754–3764.

[10] Breit HC, Block TK, Winkel DJ, Gehweiler JE, Glessgen CG, Seifert H, et al. Revisiting DCE-MRI. Investigative Radiology. 2021; 56: 553–562.

[11] Nakanishi K, Tanaka J, Nakaya Y, Maeda N, Sakamoto A, Nakayama A, et al. Whole-body MRI: detecting bone metastases from prostate cancer. Japanese Journal of Radiology. 2022; 40: 229–244.

[12] Hectors SJ, Said D, Gnerre J, Tewari A, Taouli B. Luminal water imaging: comparison with diffusion‐weighted imaging (DWI) and PI‐RADS for characterization of prostate cancer aggressiveness. Journal of Magnetic Resonance Imaging. 2020; 52: 271–279.

[13] De Perrot T, Sadjo Zoua C, Glessgen CG, Botsikas D, Berchtold L, Salomir R, et al. Diffusion-weighted MRI in the genitourinary system. Journal of Clinical Medicine. 2022; 11: 1921.

[14] Jiang J, Li J, Xiong X, Zhang S, Tan D, Yang L, et al. Different predictive values of microvessel density for biochemical recurrence among different PCa populations: a systematic review and meta-analysis. Cancer Medicine. 2023; 12: 2166–2178.

[15] Malyarenko DI, Swanson SD, McGarry SD, LaViolette PS, Chenevert TL. The impeded diffusion fraction quantitative imaging assay demonstrated in multi-exponential diffusion phantom and prostate cancer. Magnetic Resonance in Medicine. 2022; 87: 2053–2062.

[16] Dorairajan L, Dutt U, Kumar S, Badhe B, Manikandan R, Singh S. Effect of preoperative finasteride on perioperative blood loss during transurethral resection of the prostate and on microvessel density in patients with benign prostatic hyperplasia: an open label randomized controlled trial. Urology Annals. 2021; 13: 199.

[17] Li J, Ren Q, Shangguan J, Feng X, Ma X. Imaging features of dermatofibrosarcoma protuberans. Journal of Cancer Research and Therapeutics. 2022; 18: 476.

[18] Ziayee F, Mueller-Lutz A, Gross J, Ullrich T, Quentin M, Arsov C, et al. Arterial input function for quantitative dynamic contrast-enhanced MRI to diagnose prostate cancer. Diagnostic and Interventional Radiology. 2022; 28: 108–114.

[19] Abreu-Gomez J, Lim C, Cron GO, Krishna S, Sadoughi N, Schieda N. Pharmacokinetic modeling of dynamic contrast-enhanced (DCE)-MRI in PI-RADS category 3 peripheral zone lesions: preliminary study evaluating DCE-MRI as an imaging biomarker for detection of clinically significant prostate cancers. Abdominal Radiology. 2021; 46: 4370–4380.

[20] Akbari H, Kazerooni AF, Ware JB, Mamourian E, Anderson H, Guiry S, et al. Quantification of tumor microenvironment acidity in glioblastoma using principal component analysis of dynamic susceptibility contrast enhanced MR imaging. Scientific Reports. 2021; 11: 15011.

[21] Van Den Berghe T, Verstraete KL, Lecouvet FE, Lejoly M, Dutoit J. Review of diffusion-weighted imaging and dynamic contrast-enhanced MRI for multiple myeloma and its precursors (monoclonal gammopathy of undetermined significance and smouldering myeloma). Skeletal Radiology. 2022; 51: 101–122.

[22] Li Z, Xian M, Guo J, Wang CS, Zhang L, Xian J. Dynamic contrast-enhanced MRI can quantitatively identify malignant transformation of sinonasal inverted papilloma. The British Journal of Radiology. 2022; 95: 20211374.

[23] Yaligar J, Verma SK, Gopalan V, Anantharaj R, Thu Le GT, Kaur K, et al. Dynamic contrast‐enhanced MRI of brown and beige adipose tissues. Magnetic Resonance in Medicine. 2020; 84: 384–395.

[24] Stocker D, Hectors S, Bane O, Vietti-Violi N, Said D, Kennedy P, et al. Dynamic contrast-enhanced MRI perfusion quantification in hepatocellular carcinoma: comparison of gadoxetate disodium and gadobenate dimeglumine. European Radiology. 2021; 31: 9306–9315.

[25] Coll-Font J, Afacan O, Chow JS, Lee RS, Warfield SK, Kurugol S. Modeling dynamic radial contrast enhanced MRI with linear time invariant systems for motion correction in quantitative assessment of kidney function. Medical Image Analysis. 2021; 67: 101880.

[26] Kong L, Qi R, Zhou G, Ding S. Correlation analysis of survivin, ING4, CXCL8 and VEGF expression in prostate cancer tissue. American Journal of Translational Research. 2021; 13: 13784–13790.

[27] Larsson P, Syed Khaja AS, Semenas J, Wang T, Sarwar M, Dizeyi N, et al. The functional interlink between AR and MMP9/VEGF signaling axis is mediated through PIP5K1α/pAKT in prostate cancer. International Journal of Cancer. 2020; 146: 1686–1699.

[28] Leis‐Filho AF, Lainetti PD, Kobayashi PE, Palmieri C, Amorim RL, Fonseca-Alves CE. Expression and prognostic significance of vascular endothelial growth factor-a (VEGF-a) and its receptor in canine prostate cancer. The Prostate. 2021; 81: 1021–1031.

[29] Abdelmaksoud IR, Shalaby A, Mahmoud A, Elmogy M, Aboelfetouh A, Abou El-Ghar M, et al. Precise identification of prostate cancer from DWI using transfer learning. Sensors. 2021; 21: 3664.

[30] Yao W, Liu J, Zheng J, Lu P, Zou S, Xu Y. Study on diagnostic value of quantitative parameters of intravoxel incoherent motion diffusion-weighted imaging (IVIM-DWI) in prostate cancer. American Journal of Translational Research. 2021; 13: 3696–3702.

[31] Hammon M, Saake M, Laun FB, Heiss R, Seuss N, Janka R, et al. Improved visualization of prostate cancer using multichannel computed diffusion images: combining ADC and DWI. Diagnostics. 2022; 12: 1592.